Skip to main content
Howard Colman, MD, Neurology, Salt Lake City, UT, University of Utah Health

HowardColmanMDPhD, FAAN

Neurology • Salt Lake City, UT

Neurooncology

Professor and Jon M. Hunstman Chair in Neuro-Oncology, Huntsman Cancer Institute and Dept. of Neurosurgery, University of Utah School of Medicine

Join to view full profile

Dr. Colman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Colman's full profile

Already have an account?

Summary

  • HOWARD COLMAN, MD, PHD. (Updated September 2021)
    SELECTED KEY APPOINTMENTS:
    Jon M. Huntsman Presidential Chair of Neuro-Oncology
    Professor, Depts. of Neurosurgery, Neurology, and Internal Medicine (Oncology), Univ. of Utah
    Investigator, Huntsman Cancer Institute
    Co-Leader, Experimental Therapeutics Program
    Co-Leader, Neurologic Cancers Center, Huntsman Cancer Institute

    Dr. Howard Colman is a Professor (Tenured) in the Depts. of Neurosurgery, Neurology, and Internal Medicine (Oncology). He is Leader of the Center for Neurologic Cancers at HCI. He is also former Medical Director of Neuro-Oncology at Intermountain Medical Center, and former Acting Chair of Hematology and Oncology at the Salt Lake City VA Hospital. Dr. Colman received his M.D. and a Ph.D. in Neuroscience from Washington University School of Medicine in St. Louis, Missouri. He completed a Neuro-Oncology fellowship at the UT MD Anderson Cancer Center in Houston, Texas and is board-certified in Neurology and Neuro-Oncology. Dr. Colman divides his time between patient care and clinical and laboratory research. Dr. Colman's clinical interests are treatment of primary and metastatic brain tumors and diagnosis and management of neurologic complications of cancer. His clinical research is focused on developing and testing new therapies for brain tumors. His laboratory interests are identification of molecular markers of prognosis and treatment response in brain tumors, and the role of tumor stem cells in the development and treatment of resistance of brain tumors. Dr. Colman has been PI and co-investigator on multiple brain tumor clinical trials and grants. Dr. Colman is currently the HCI P.I. for the Alliance for Clinical Trials in Oncology cooperative group, a member of the Board of Directors for Alliance, and a member of the Neuro-Oncology Committee for Alliance. He is a member of the steering committee for the HCI U10 cooperative groups grant. He has served as PI, Co-I, or Project Leader on mul

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 1998 - 2001
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1997 - 1998
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 1997

Certifications & Licensure

  • UT State Medical License
    UT State Medical License 2010 - 2026
  • WY State Medical License
    WY State Medical License 2021 - 2024
  • TX State Medical License
    TX State Medical License 2001 - 2012
  • American Board of Psychiatry and Neurology Neurology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Opportunities for Investigating Novel Molecular Targets Including PARP/IDH/Fusions in Glioblastoma 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Huntsman Cancer Institute Announces Howard Colman, MD, PhD, as Experimental Therapeutics Program Co-Leader
    Huntsman Cancer Institute Announces Howard Colman, MD, PhD, as Experimental Therapeutics Program Co-LeaderJuly 28th, 2021
  • FDA Clears Samus Drug for Glioma Phase Ib Study
    FDA Clears Samus Drug for Glioma Phase Ib StudyMay 11th, 2021
  • Neurosurgeons in Utah County
    Neurosurgeons in Utah CountyFebruary 24th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Howard Colman, Dr. Howard Colman, MD, Dr. H Colman